Heparin administration increases plasma warfarin binding in man.

Unaltered serum propranolol binding by meal‐induced variations in fatty acids.

“…Several in vivo and in vitro studies have shown that variations in FFAs can be correlated with changes in the binding of drugs (Naranjo et al, 1980a, b;Birkett et al, 1979;Wood et al, 1979). However, examples of dissociation between heparin-induced increases in FFAs and variations in warfarin (Routledge et al, 1979;Naranjo et al, 1980b), diazepam (Naranjo et al, 1980b;Naranjo et al, 1982) and propranolol binding have been reported (Naranjo et al, 1982). Further- more, dissociation between increases in FFAs and variations in drug binding have also been observed after caffeine administration (Patwardthan et al, 1980).…”

Influence of Uremia and Hemodialysis on the Plasma Protein Binding of Tolmetin

“…21], addition of NEFAs increased tolmetin binding to plasma proteins. NEFAs bind to human plasma albumin with high affinity and may enhance tolmetin-binding receptor affinity, possibly through an alloste ric interaction [22], Similar effects of NEFAs have been observed for warfarin [8], quinidine [22] and zomepirac [15] binding to hu man plasma proteins.…”

“…In addition to the effects of the disease state itself, hemodialysis can influence drug binding. Removal of excess body water in creases the concentration of binding protein for a period of time after hemodialysis [1.4], Heparin, administered during hemodialysis, may increase plasma nonesterified fatty acids (NEFA), known modifiers of drug binding to plasma proteins [7,8]. Therefore, both the severity of renal failure and the therapy being administered to uremic patients must be con sidered when evaluating the influence of this disease state on drug binding to plasma pro teins.…”

Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.

“…We cannot exclude the possibility that the heparinized saline with which the i.v. cannulae were flushed might have altered the protein binding of disopyramide; this effect has been shown in the case of propranolol (Wood, Shand & Wood, 1979), warfarin (Routledge, Bjornsson, Kitchell & Shand, 1979), digoxin (Storstein & Janssen, 1976) and quinidine (Nilsen, Storstein & Jacobsen, 1977) but not as yet for disopyramide. Taking the dosage interval as 8 h, the desired average plasma level as 4 mg 11 (Heel et al, 1978), and the bioavailability of disopyramide as 0.8 (Bryson, Whiting & Lawrence, 1978) A 70 kg man with renal impainnent might therefore be expected to require 100 mg disopyramide base thrice daily.…”

“…We cannot exclude the possibility that the heparinized saline with which the i.v. cannulae were flushed might have altered the protein binding of disopyramide; this effect has been shown in the case of propranolol (Wood, Shand & Wood, 1979), warfarin (Routledge, Bjornsson, Kitchell & Shand, 1979), digoxin (Storstein & Janssen, 1976) and quinidine (Nilsen, Storstein & Jacobsen, 1977) but not as yet for disopyramide. Table 2 Pharnacokinetic parameters for disopyramide in patients with chronic renal impairment.…”